Open AccessAbstract CT236: A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis
Author(s) -
Eduardo Vilar-Sanchez,
Carol A. Burke,
Marcia R. Cruz Correa,
Evelien Dekker,
William M. Grady,
Philippe Grandval,
Bryson W. Katona,
Xavier Llor,
Douglas L. RiegertJohnson,
JeanChristophe Saurin,
Peter P. Stanich,
Daniel A. Sussman,
David S. Weinberg,
Edward F. Attiyeh,
Devanand Joseph,
Kelly Raybold,
Gary Borzillo,
Thomas Prior,
M. Hamblin Smith,
Haiyang Xie,
Kurtis E. Bachman,
Jeffrey R. Infante,
N. Jewel Samadder
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct236
Subject(s) - familial adenomatous polyposis , medicine , gastroenterology , colorectal cancer , adenomatous polyposis coli , dysplasia , celecoxib , colectomy , pouchitis , oncology , cancer , ulcerative colitis , disease